Clinical Trials Directory

Trials / Terminated

TerminatedNCT02843880

Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study

Predictive Factors of Cytomegalovirus Reactivation or Cytomegalovirus Disease by Immunological Study of Immunocompetent Patients Hospitalized for Septic Shock

Status
Terminated
Phase
Study type
Observational
Enrollment
1 (actual)
Sponsor
AdministrateurDRC · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Cytomegalovirus is a herpesviridae whose prevalence in general population is between 50 to 80%. In immunocompetent individuals, CMV remains latent in a number of cells, without any pathological consequence. Immunosuppression may reactivate the virus causing either a CMV-active infection or a CMV disease with attributable symptoms. In Intensive Care Unit (ICU), 6 to 30 % of critically ill patients without classical immunosuppression, as those suffering from septic shock, present CMV reactivation. Our aim is to study the risk factors for developing viremia or CMV disease in ICU patients in septic shock without previous immunodepression and determine the relationship between viral reactivation and this acquired immunity alteration.

Detailed description

Immunosuppression statuses causing both CMV active infection or disease are mainly consecutive to HIV infection, bone marrow or solid organ transplantation. However, in severely ill patients, as in septic shock, it has been proved that after a hyper-inflammatory phase occurred a negative control of the immunity, resulting in a paralysed or impaired immune system. The length and extent of this immunodeficiency is correlated with the duration of ICU stay, the occurrence of nosocomial infection and mortality. A better understanding of CMV's natural history reactivation in the critically ill patient would better define the benefits from a specific therapy.

Conditions

Timeline

Start date
2013-03-01
Primary completion
2016-05-01
Completion
2016-05-01
First posted
2016-07-26
Last updated
2016-07-26

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02843880. Inclusion in this directory is not an endorsement.